Tags

Type your tag names separated by a space and hit enter

Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach.
Int J Biol Macromol. 2020 Nov 01; 162:820-837.IJ

Abstract

SARS-CoV-2 is the deadly virus behind COVID-19, the disease that went on to ravage the world and caused the biggest pandemic 21st century has witnessed so far. On the face of ongoing death and destruction, the urgent need for the discovery of a vaccine against the virus is paramount. This study resorted to the emerging discipline of immunoinformatics in order to design a multi-epitope mRNA vaccine against the spike glycoprotein of SARS-CoV-2. Various immunoinformatics tools were utilized to predict T and B lymphocyte epitopes. The epitopes were channeled through a filtering pipeline comprised of antigenicity, toxicity, allergenicity, and cytokine inducibility evaluation with the goal of selecting epitopes capable of generating both T and B cell-mediated immune responses. Molecular docking simulation between the epitopes and their corresponding MHC molecules was carried out. 13 epitopes, a highly immunogenic adjuvant, elements for proper sub-cellular trafficking, a secretion booster, and appropriate linkers were combined for constructing the vaccine. The vaccine was found to be antigenic, almost neutral at physiological pH, non-toxic, non-allergenic, capable of generating a robust immune response and had a decent worldwide population coverage. Based on these parameters, this design can be considered a promising choice for a vaccine against SARS-CoV-2.

Authors+Show Affiliations

Department of Biochemistry and Microbiology, North South University, Dhaka 1229, Bangladesh. Electronic address: ishtiaque.ahammad@northsouth.edu.Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka 1000, Bangladesh.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32599237

Citation

Ahammad, Ishtiaque, and Samia Sultana Lira. "Designing a Novel mRNA Vaccine Against SARS-CoV-2: an Immunoinformatics Approach." International Journal of Biological Macromolecules, vol. 162, 2020, pp. 820-837.
Ahammad I, Lira SS. Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach. Int J Biol Macromol. 2020;162:820-837.
Ahammad, I., & Lira, S. S. (2020). Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach. International Journal of Biological Macromolecules, 162, 820-837. https://doi.org/10.1016/j.ijbiomac.2020.06.213
Ahammad I, Lira SS. Designing a Novel mRNA Vaccine Against SARS-CoV-2: an Immunoinformatics Approach. Int J Biol Macromol. 2020 Nov 1;162:820-837. PubMed PMID: 32599237.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach. AU - Ahammad,Ishtiaque, AU - Lira,Samia Sultana, Y1 - 2020/06/26/ PY - 2020/05/03/received PY - 2020/06/16/revised PY - 2020/06/22/accepted PY - 2020/7/1/pubmed PY - 2020/10/21/medline PY - 2020/6/30/entrez KW - Immunoinformatics KW - SARS-CoV-2 KW - mRNA vaccine SP - 820 EP - 837 JF - International journal of biological macromolecules JO - Int J Biol Macromol VL - 162 N2 - SARS-CoV-2 is the deadly virus behind COVID-19, the disease that went on to ravage the world and caused the biggest pandemic 21st century has witnessed so far. On the face of ongoing death and destruction, the urgent need for the discovery of a vaccine against the virus is paramount. This study resorted to the emerging discipline of immunoinformatics in order to design a multi-epitope mRNA vaccine against the spike glycoprotein of SARS-CoV-2. Various immunoinformatics tools were utilized to predict T and B lymphocyte epitopes. The epitopes were channeled through a filtering pipeline comprised of antigenicity, toxicity, allergenicity, and cytokine inducibility evaluation with the goal of selecting epitopes capable of generating both T and B cell-mediated immune responses. Molecular docking simulation between the epitopes and their corresponding MHC molecules was carried out. 13 epitopes, a highly immunogenic adjuvant, elements for proper sub-cellular trafficking, a secretion booster, and appropriate linkers were combined for constructing the vaccine. The vaccine was found to be antigenic, almost neutral at physiological pH, non-toxic, non-allergenic, capable of generating a robust immune response and had a decent worldwide population coverage. Based on these parameters, this design can be considered a promising choice for a vaccine against SARS-CoV-2. SN - 1879-0003 UR - https://www.unboundmedicine.com/medline/citation/32599237/Designing_a_novel_mRNA_vaccine_against_SARS_CoV_2:_An_immunoinformatics_approach_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0141-8130(20)33665-5 DB - PRIME DP - Unbound Medicine ER -